MORISHITA JINTAN CO., LTD.
4524・Standard Market・Pharmaceuticals
Governance
The company is a company with an audit and supervisory committee (transitioned in 2018). The Board of Directors consists of 7 members (4 of whom are outside directors), and a Nomination and Compensation Advisory Committee has been established as an advisory body to the Board of Directors to ensure transparency and fairness in management.
Risk Management
The company has established a Risk Management Committee chaired by the Representative Director and President, building a cross-functional risk management framework based on the Risk Management Regulations. It collaborates with the Sustainability Promotion Committee to identify and assess risks and formulate response policies, and reports regularly to the Board of Directors.
Shareholder Returns
The basic policy is to pay dividends twice a year (interim and year-end). The year-end dividend for FY2026 (ending March 2026) is ¥65 per share (total dividends of ¥266 million, payout ratio 42.3%). The same amount of ¥65 is forecast for FY2027 (ending March 2027). Share buybacks can be executed flexibly based on provisions in the Articles of Incorporation.
Dividend Policy
The basic policy is to pay dividends twice a year, comprising an interim dividend and a year-end dividend. For FY2026 (ending March 2026), the year-end dividend is ¥65 per share (total dividends of ¥266 million, payout ratio 42.3%, net asset dividend rate 2.1%). In the previous fiscal year (FY2025, ended March 2025), the dividend was ¥55 per share (total dividends of ¥225 million, payout ratio 41.1%). For FY2027 (ending March 2027), the forecast is ¥65 per share (payout ratio forecast at 50.2%).
ESG
The company has identified five materiality issues centered around the Sustainability Promotion Committee, and has set a target of reducing CO₂ emissions by 46% by FY2030 compared to FY2013 levels. In terms of human capital,
Last updated: June 22, 2026